Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: A case-control study

N. L. Henry, D. Pchejetski, R. A'Hern, A. T. Nguyen, P. Charles, J. Waxman, L. Li, Anna Maria Storniolo, D. F. Hayes, D. A. Flockhart, V. Stearns, J. Stebbing

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background:The aromatase inhibitor (AI)-associated musculoskeletal syndrome (AIMSS) occurs in approximately 50% of AI-treated patients. Inflammatory mediators are associated with oestrogen signalling and may change with oestrogen depletion. We hypothesised that AIMSS may be associated with changes in circulating inflammatory markers.Methods:Patients with breast cancer were enroled in a trial of adjuvant AI therapy. Changes in pain and function during therapy were assessed prospectively. We selected 30 cases with AIMSS and 22 controls without AIMSS, matched for demographics and prior therapy. Serum samples collected at baseline and during treatment were assayed for multiple inflammatory cytokines and lipid mediators using multiplex assays.Results:Before AI therapy, mean serum concentrations of 6 of 36 assayed factors were statistically significantly lower in cases than controls (all P<0.003). No statistically significant changes during AI therapy relative to pre-treatment were observed between cases and controls for any of the inflammatory markers tested.Conclusion:AIMSS is probably not associated with a systemic inflammatory response. Pre-treatment cytokine levels may predict for development of AIMSS.

Original languageEnglish
Pages (from-to)291-296
Number of pages6
JournalBritish Journal of Cancer
Volume103
Issue number3
DOIs
StatePublished - Jul 27 2010

Fingerprint

Aromatase Inhibitors
Case-Control Studies
Cytokines
Therapeutics
Estrogens
Musculoskeletal Development
Serum
Demography
Breast Neoplasms
Lipids
Pain

Keywords

  • aromatase inhibitor
  • arthralgia
  • breast cancer
  • cytokine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Henry, N. L., Pchejetski, D., A'Hern, R., Nguyen, A. T., Charles, P., Waxman, J., ... Stebbing, J. (2010). Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: A case-control study. British Journal of Cancer, 103(3), 291-296. https://doi.org/10.1038/sj.bjc.6605768

Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome : A case-control study. / Henry, N. L.; Pchejetski, D.; A'Hern, R.; Nguyen, A. T.; Charles, P.; Waxman, J.; Li, L.; Storniolo, Anna Maria; Hayes, D. F.; Flockhart, D. A.; Stearns, V.; Stebbing, J.

In: British Journal of Cancer, Vol. 103, No. 3, 27.07.2010, p. 291-296.

Research output: Contribution to journalArticle

Henry, NL, Pchejetski, D, A'Hern, R, Nguyen, AT, Charles, P, Waxman, J, Li, L, Storniolo, AM, Hayes, DF, Flockhart, DA, Stearns, V & Stebbing, J 2010, 'Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: A case-control study', British Journal of Cancer, vol. 103, no. 3, pp. 291-296. https://doi.org/10.1038/sj.bjc.6605768
Henry, N. L. ; Pchejetski, D. ; A'Hern, R. ; Nguyen, A. T. ; Charles, P. ; Waxman, J. ; Li, L. ; Storniolo, Anna Maria ; Hayes, D. F. ; Flockhart, D. A. ; Stearns, V. ; Stebbing, J. / Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome : A case-control study. In: British Journal of Cancer. 2010 ; Vol. 103, No. 3. pp. 291-296.
@article{0bc669e9e6194f77beb186784b4fafb6,
title = "Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: A case-control study",
abstract = "Background:The aromatase inhibitor (AI)-associated musculoskeletal syndrome (AIMSS) occurs in approximately 50{\%} of AI-treated patients. Inflammatory mediators are associated with oestrogen signalling and may change with oestrogen depletion. We hypothesised that AIMSS may be associated with changes in circulating inflammatory markers.Methods:Patients with breast cancer were enroled in a trial of adjuvant AI therapy. Changes in pain and function during therapy were assessed prospectively. We selected 30 cases with AIMSS and 22 controls without AIMSS, matched for demographics and prior therapy. Serum samples collected at baseline and during treatment were assayed for multiple inflammatory cytokines and lipid mediators using multiplex assays.Results:Before AI therapy, mean serum concentrations of 6 of 36 assayed factors were statistically significantly lower in cases than controls (all P<0.003). No statistically significant changes during AI therapy relative to pre-treatment were observed between cases and controls for any of the inflammatory markers tested.Conclusion:AIMSS is probably not associated with a systemic inflammatory response. Pre-treatment cytokine levels may predict for development of AIMSS.",
keywords = "aromatase inhibitor, arthralgia, breast cancer, cytokine",
author = "Henry, {N. L.} and D. Pchejetski and R. A'Hern and Nguyen, {A. T.} and P. Charles and J. Waxman and L. Li and Storniolo, {Anna Maria} and Hayes, {D. F.} and Flockhart, {D. A.} and V. Stearns and J. Stebbing",
year = "2010",
month = "7",
day = "27",
doi = "10.1038/sj.bjc.6605768",
language = "English",
volume = "103",
pages = "291--296",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome

T2 - A case-control study

AU - Henry, N. L.

AU - Pchejetski, D.

AU - A'Hern, R.

AU - Nguyen, A. T.

AU - Charles, P.

AU - Waxman, J.

AU - Li, L.

AU - Storniolo, Anna Maria

AU - Hayes, D. F.

AU - Flockhart, D. A.

AU - Stearns, V.

AU - Stebbing, J.

PY - 2010/7/27

Y1 - 2010/7/27

N2 - Background:The aromatase inhibitor (AI)-associated musculoskeletal syndrome (AIMSS) occurs in approximately 50% of AI-treated patients. Inflammatory mediators are associated with oestrogen signalling and may change with oestrogen depletion. We hypothesised that AIMSS may be associated with changes in circulating inflammatory markers.Methods:Patients with breast cancer were enroled in a trial of adjuvant AI therapy. Changes in pain and function during therapy were assessed prospectively. We selected 30 cases with AIMSS and 22 controls without AIMSS, matched for demographics and prior therapy. Serum samples collected at baseline and during treatment were assayed for multiple inflammatory cytokines and lipid mediators using multiplex assays.Results:Before AI therapy, mean serum concentrations of 6 of 36 assayed factors were statistically significantly lower in cases than controls (all P<0.003). No statistically significant changes during AI therapy relative to pre-treatment were observed between cases and controls for any of the inflammatory markers tested.Conclusion:AIMSS is probably not associated with a systemic inflammatory response. Pre-treatment cytokine levels may predict for development of AIMSS.

AB - Background:The aromatase inhibitor (AI)-associated musculoskeletal syndrome (AIMSS) occurs in approximately 50% of AI-treated patients. Inflammatory mediators are associated with oestrogen signalling and may change with oestrogen depletion. We hypothesised that AIMSS may be associated with changes in circulating inflammatory markers.Methods:Patients with breast cancer were enroled in a trial of adjuvant AI therapy. Changes in pain and function during therapy were assessed prospectively. We selected 30 cases with AIMSS and 22 controls without AIMSS, matched for demographics and prior therapy. Serum samples collected at baseline and during treatment were assayed for multiple inflammatory cytokines and lipid mediators using multiplex assays.Results:Before AI therapy, mean serum concentrations of 6 of 36 assayed factors were statistically significantly lower in cases than controls (all P<0.003). No statistically significant changes during AI therapy relative to pre-treatment were observed between cases and controls for any of the inflammatory markers tested.Conclusion:AIMSS is probably not associated with a systemic inflammatory response. Pre-treatment cytokine levels may predict for development of AIMSS.

KW - aromatase inhibitor

KW - arthralgia

KW - breast cancer

KW - cytokine

UR - http://www.scopus.com/inward/record.url?scp=77955051102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955051102&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6605768

DO - 10.1038/sj.bjc.6605768

M3 - Article

C2 - 20606683

AN - SCOPUS:77955051102

VL - 103

SP - 291

EP - 296

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 3

ER -